List of Excipients in Branded Drug NEXT CHOICE ONE DOSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	LACTOSE MONOHYDRATE
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	MAGNESIUM STEARATE
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	SILICON DIOXIDE
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	STARCH, CORN
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	STARCH, POTATO
Foundation Consumer Healthcare LLC	NEXT CHOICE ONE DOSE	levonorgestrel	69536-133	TALC

Next Choice One Dose Excipient Strategy and Commercial Opportunities

Last updated: October 27, 2026

Next Choice One Dose is a levonorgestrel 1.5 mg emergency contraceptive tablet. Its commercial value is driven by rapid disintegration, low-cost manufacture, broad OTC substitution, and reliable shelf life rather than by active-ingredient exclusivity. The product’s likely excipient platform is conventional and readily design-aroundable. The strongest opportunities are private-label OTC supply, lactose-free reformulation, improved packaging, regional distribution, and differentiated dosage forms.

What is Next Choice One Dose and how is it regulated?

Next Choice One Dose contains 1.5 mg of levonorgestrel in a single oral tablet. Levonorgestrel is a synthetic progestin used for emergency contraception after unprotected intercourse or contraceptive failure.

The U.S. product was developed as a single-tablet alternative to the earlier two-tablet Next Choice product. FDA-approved levonorgestrel emergency contraceptives have since faced extensive generic competition and limited product differentiation [1].

Product attribute	Next Choice One Dose
Active ingredient	Levonorgestrel
Strength	1.5 mg
Dosage form	Immediate-release oral tablet
Primary use	Emergency contraception
FDA pathway	Abbreviated New Drug Application or NDA-related levonorgestrel pathway, depending on product sponsor
Originator market	Prescription and OTC emergency contraception
Key commercial channels	Pharmacies, mass retail, e-commerce, public health procurement, private label
Core technical requirement	Fast and consistent release of a low-dose active

Plan B One-Step established the U.S. single-dose levonorgestrel emergency-contraception market. Other products, including Next Choice One Dose, compete primarily through price, availability, retailer access, and supply reliability rather than through clinically differentiated pharmacology [2].

What excipients are used in Next Choice One Dose?

Public labeling identifies a conventional immediate-release tablet system. Reported inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, polacrilin potassium, colloidal silicon dioxide, and magnesium stearate. Exact quantities and manufacturing parameters are generally not disclosed in the commercial label [3].

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet-volume builder	Low cost, established supply, but unsuitable for lactose-free positioning
Microcrystalline cellulose	Filler and dry-binder	Supports direct compression and tablet strength
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Polacrilin potassium	Disintegrant and resinous excipient	Supports rapid water uptake and dispersion
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Film-coating materials, if used	Appearance, swallowability, protection	Can add taste and handling benefits

This excipient system is not intrinsically difficult to reproduce. The manufacturing challenge is content uniformity because the levonorgestrel dose is small relative to total tablet mass. Blend segregation, lubricant overmixing, and poor distribution of the active can affect assay and uniformity.

How should an excipient strategy be designed for levonorgestrel 1.5 mg tablets?

The formulation objective is a robust immediate-release tablet with rapid disintegration, acceptable mechanical strength, and low manufacturing cost. The most practical strategy is a direct-compression or dry-granulation platform using a high-functionality filler and one or more superdisintegrants.

Content uniformity

Levonorgestrel represents a small fraction of tablet weight. A commercial process should prioritize:

• Geometric dilution of levonorgestrel into a portion of microcrystalline cellulose or another carrier.
• Controlled particle-size distribution.
• Low-segregation powder handling.
• Validated blend sampling.
• Tight control of transfer and hopper residence time.
• Lubricant addition late in the process.

Wet granulation can improve blend uniformity but may increase process complexity and moisture exposure. Direct compression is commercially attractive if the active and excipient particle-size distributions are well matched.

Disintegration and dissolution

Emergency contraception depends on prompt oral delivery, although the product does not require an extended-release system. Croscarmellose sodium, crospovidone, sodium starch glycolate, or polacrilin potassium can be used separately or in combination.

A reformulator should optimize:

• Superdisintegrant concentration.
• Intra- and extra-granular placement where granulation is used.
• Tablet porosity.
• Compression force.
• Lubricant concentration and mixing time.
• Dissolution performance after accelerated storage.

Excessive compression or over-lubrication can delay water penetration. A tablet that is mechanically strong but slow to disintegrate creates avoidable regulatory and commercial risk.

Moisture and stability

Levonorgestrel tablets require protection from uncontrolled moisture and heat during manufacturing, distribution, and storage. The practical controls are:

• Low-moisture excipients where justified.
• Moisture-barrier blister packaging.
• Desiccant-containing secondary packaging for selected markets.
• Stability testing under ICH conditions.
• Protection from excessive tablet friability during shipment.

Packaging may produce a stronger commercial advantage than a novel excipient. A low-cost blister with strong moisture protection can support longer shelf life, fewer damaged units, and better performance in hot or humid distribution environments.

What formulation improvements could create commercial opportunities?

The existing conventional tablet leaves room for targeted improvements. The strongest opportunities are not broad claims of “better absorption.” They are measurable improvements in usability, manufacturing, packaging, or market access.

Lactose-free emergency contraception

Replacing lactose with mannitol, dibasic calcium phosphate, spray-dried cellulose, or a co-processed excipient can support a lactose-free product. The opportunity is commercially credible but must be balanced against:

• Different compactability.
• Changed tablet mouthfeel.
• Possible dissolution differences.
• New excipient compatibility work.
• Separate stability and bioequivalence requirements.

A lactose-free claim may help pharmacy and private-label buyers, although it does not by itself establish meaningful clinical differentiation.

Orally disintegrating or rapidly dispersible tablets

An orally disintegrating tablet could target consumers who have difficulty swallowing or need discreet administration. Mannitol-based systems, crospovidone, porous compression, and taste-masking coatings are possible approaches.

The primary obstacle is taste. Levonorgestrel products can require taste masking because the tablet may remain in the mouth during administration. A rapidly disintegrating product without adequate taste control may be less acceptable than a conventional swallowable tablet.

Potential intellectual-property positions include:

• Taste-masked levonorgestrel particles.
• A defined disintegration-time range.
• Specific mannitol-polymer combinations.
• Moisture-protective packaging for an ODT.
• A process that improves content uniformity in a low-dose ODT.

Smaller tablets and unit-dose packaging

A smaller tablet can improve swallowing and reduce material use. Unit-dose blister packaging can support:

• Pharmacy dispensing.
• Public-sector procurement.
• Travel and emergency kits.
• Retail shelf stability.
• Anti-counterfeiting measures.

Packaging patents may be more defensible than broad excipient claims if the invention uses a specific barrier structure, tamper feature, or moisture-control configuration.

Pediatric and global-market adaptations

Emergency contraception is generally used by post-pubertal individuals, so a pediatric formulation is not the main opportunity. Regional opportunities are stronger in countries where access, language, pack size, and heat stability influence procurement.

Potential adaptations include:

• Multilingual labeling.
• Compact blister packs.
• High-temperature stability.
• Lower-cost bottle packaging where moisture protection remains adequate.
• Products compatible with local regulatory requirements for nonprescription sale.

What patents protect Next Choice One Dose?

The active ingredient, levonorgestrel, is an established compound and does not provide a meaningful new-molecule patent barrier for Next Choice One Dose. The commercial patent risk therefore depends on formulation, manufacturing, packaging, and method-of-use claims.

A conventional levonorgestrel 1.5 mg immediate-release tablet is unlikely to support a strong composition-of-matter patent. Potentially protectable subject matter includes:

Patent category	Potential claim scope	Expected strength
Excipient composition	Defined filler-disintegrant-lubricant system	Low to moderate unless tied to unexpected performance
Taste masking	Coated particles or polymeric matrix	Moderate if supported by sensory and dissolution data
ODT formulation	Specific porous matrix and disintegration profile	Moderate
Manufacturing process	Content-uniformity or segregation-control process	Moderate, often better protected as a trade secret
Packaging	Moisture-barrier blister or unit-dose system	Moderate
Method of use	Emergency contraception dosing regimen	Generally limited where prior art is extensive
Combination product	Levonorgestrel with another contraceptive active	Potentially stronger, but requires new clinical and regulatory work

A credible formulation patent should define the composition with numerical ranges and demonstrate a technical effect, such as faster disintegration, improved stability, reduced variability, or better taste. Broad claims covering ordinary excipient substitutions are vulnerable to written-description, enablement, obviousness, and lack-of-unexpected-results challenges.

What is the Orange Book status of Next Choice One Dose?

Orange Book protection is unlikely to be the primary barrier for a levonorgestrel generic or private-label product. FDA Orange Book analysis should distinguish among:

1. Listed patents tied to the specific NDA.
2. Patents covering the active ingredient.
3. Later formulation or packaging patents.
4. Regulatory exclusivity.
5. Market discontinuation status.

For an old, immediate-release levonorgestrel tablet, any original product exclusivity would have expired. A later formulation patent would need to be separately listed and would not automatically protect every levonorgestrel emergency-contraception tablet.

The relevant generic pathway is generally an ANDA referencing the applicable reference product. A Paragraph IV certification would matter only if an unexpired, Orange Book-listed patent were identified. For a conventional Next Choice One Dose-style tablet, the principal commercial exposure is substitution by approved generics, not a prolonged patent dispute.

When does Next Choice One Dose lose exclusivity?

Next Choice One Dose has no meaningful new chemical entity exclusivity remaining. Levonorgestrel emergency contraception has been commercially available for many years, and the U.S. market contains multiple generic and branded alternatives.

The practical exclusivity timeline is:

Event	Commercial implication
Original levonorgestrel approval	Established the regulatory and clinical basis
Single-dose product approval	Reduced dosing burden
OTC expansion of levonorgestrel emergency contraception	Expanded consumer access
Generic approvals	Shifted competition to price and supply
Mature market	Limited room for active-ingredient exclusivity

Product-level revenue for Next Choice One Dose is not separately disclosed in public filings. Revenue exposure is therefore best assessed at the category level, including private-label contracts, retail distribution, and institutional procurement.

Which companies are challenging or competing with Next Choice One Dose?

The competitive set includes:

• Plan B One-Step and related products.
• Generic levonorgestrel 1.5 mg tablets.
• Retailer-branded emergency contraceptives.
• International levonorgestrel products.
• ella, which contains ulipristal acetate and has a different regulatory and clinical profile.
• Copper intrauterine contraception, which is a nonoral emergency-contraception option.

The most relevant direct competitors are generic levonorgestrel 1.5 mg tablets. These products typically use similar excipient functions and compete through manufacturing cost, channel access, product availability, and packaging.

Ulipristal acetate is a therapeutic alternative but not a direct formulation substitute. It has different labeling, prescription history, interaction considerations, and regulatory positioning.

What generic launch risks exist?

A generic or private-label launch faces five main risks.

Regulatory risk

The product must meet requirements for assay, content uniformity, dissolution, impurities, stability, and bioequivalence where applicable. A conventional excipient change can still alter dissolution or product performance.

Manufacturing risk

Low-dose blend uniformity is the principal process risk. Excessive tablet hardness, lubricant overmixing, and segregation can produce failures even when the formulation is chemically simple.

Supply-chain risk

The product depends on reliable supply of levonorgestrel and common pharmaceutical excipients. Packaging shortages can also disrupt retail availability because emergency contraception is often purchased as a single unit.

Commercial risk

Price erosion is likely in a mature generic market. A new entrant needs a cost advantage, a retail contract, reliable fill rates, or a clear usability benefit.

Litigation risk

Patent litigation is most plausible for a differentiated ODT, taste-masked product, novel packaging system, or combination product. Litigation risk is lower for a conventional immediate-release tablet that avoids known patent claims.

How strong is the patent estate for Next Choice One Dose?

The patent estate is weak for the conventional product concept and potentially moderate for a differentiated reformulation.

A defensible development program would separate assets into three layers:

1. Formulation patents for a specific excipient system and demonstrated performance.
2. Process trade secrets for blending, granulation, compression, and scale-up.
3. Packaging patents or know-how for moisture protection and distribution stability.

Trade-secret protection may be more valuable than a broad formulation patent for blend-order, sampling, compression, and packaging controls. These processes can be difficult to detect from the finished tablet and may resist straightforward design-around efforts.

What commercial strategy offers the best return?

The highest-probability strategy is a low-cost, quality-focused generic or private-label tablet with a standard excipient platform and optimized packaging. A higher-margin strategy would use one of the following differentiators:

• Lactose-free formulation.
• Orally disintegrating or rapidly dispersible tablet.
• Improved taste masking.
• Smaller tablet.
• Heat- and moisture-resistant unit-dose blister.
• E-commerce-ready packaging.
• Multi-country regulatory package using a common formulation.

A novel excipient is not required. The product should use excipients with established regulatory histories and global supply. The business case depends on the size of the target channel, manufacturing yield, packaging cost, retailer margins, and expected price erosion.

Key Takeaways

• Next Choice One Dose is a levonorgestrel 1.5 mg immediate-release emergency contraceptive tablet.
• Its conventional excipient system is based on fillers, superdisintegrants, a glidant, and magnesium stearate.
• The principal technical issue is low-dose content uniformity, followed by disintegration, stability, and packaging.
• Levonorgestrel provides no meaningful new-molecule patent protection for a mature product.
• A conventional generic tablet has limited patent strength and substantial price competition.
• The strongest formulation opportunities are lactose-free tablets, ODTs, taste masking, and moisture-protective unit-dose packaging.
• Process know-how and packaging protection may be more commercially valuable than broad excipient patents.
• Generic launch risk is primarily regulatory, manufacturing, supply-chain, and commercial rather than patent-driven.
• Product-specific revenue is not publicly disclosed, so exposure should be modeled through category sales and channel contracts.

FAQs

Is Next Choice One Dose an OTC product?

Levonorgestrel emergency contraception is broadly available without a prescription in the United States. Product-level labeling and distribution status can vary by sponsor and market channel.

Can lactose be removed from Next Choice One Dose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler, subject to formulation, stability, dissolution, and regulatory testing.

Is levonorgestrel 1.5 mg protected by an active patent?

The active ingredient is longstanding. Any meaningful remaining protection would more likely involve a specific formulation, manufacturing process, packaging system, or combination product.

What is the best excipient for rapid disintegration?

No single excipient is universally optimal. Croscarmellose sodium, crospovidone, sodium starch glycolate, and polacrilin potassium are established options. Performance depends on concentration, particle size, compression force, and lubricant level.

Can a new company launch a generic emergency contraceptive tablet?

A company can pursue an applicable FDA abbreviated pathway if it meets regulatory, bioequivalence, quality, labeling, manufacturing, and patent-certification requirements. Commercial viability depends on cost, supply reliability, and channel access.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (2013). FDA approves Plan B One-Step emergency contraceptive for OTC use without age or point-of-sale restrictions. https://www.fda.gov/

3. National Library of Medicine. (n.d.). Next Choice One Dose levonorgestrel tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/.page/quality-guidelines